Literature DB >> 23011603

Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.

Elizabeth Comen1, Patrick G Morris, Larry Norton.   

Abstract

In breast cancer, mortality is driven by the metastatic process, whereby some cancer cells leave their primary site of origin and travel to distant vital organs. Despite improved screening and therapies to treat breast cancers, metastasis continues to undermine these advances. The pervasive albatross of metastasis necessitates improved prevention and treatment of metastasis. To this end, clinicians routinely employ post-operative or adjuvant therapy to decrease the risk of future metastasis and improve the chance for cure. This article evaluates the limitations of breast cancer therapies within the context of growth curves, and in doing so, provides new insight into the metastatic process as well as more effective means for therapeutic delivery. Two critical developments evolve from this mathematical analysis: first, the use of dose dense chemotherapy to improve survival among breast cancer patients; and second, the theory of self-seeding, which fundamentally changes our understanding of metastasis and the trajectory of drug development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011603     DOI: 10.1007/s10911-012-9267-z

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  59 in total

1.  Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.

Authors:  Monica N Fornier; Andrew D Seidman; Diana Lake; Gabriella D'Andrea; Jacqueline Bromberg; Mark Robson; Catherine Van Poznak; Katherine S Panageas; Marietta Atienza; Larry Norton; Clifford Hudis
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

2.  Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

Authors:  C Hudis; A Seidman; J Baselga; G Raptis; D Lebwohl; T Gilewski; M Moynahan; N Sklarin; D Fennelly; J P Crown; A Surbone; M Uhlenhopp; E Riedel; T J Yao; L Norton
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Tumor-to-tumor metastasis: report of a case of renal cell carcinoma metastasizing to a pancreatic endocrine neoplasm.

Authors:  Michael Cenkowski; Ian W Gibson; Belinda Lategan; Piotr M Czaykowski
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

4.  Laboratory models: some historical perspective.

Authors:  H E Skipper
Journal:  Cancer Treat Rep       Date:  1986-01

5.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

6.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Authors:  Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

7.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Results of treating 1,178 patients with breast cancer by radical mastectomy and postoperative irradiation where metastases to axillary lymph nodes occurred.

Authors:  I M Ariel
Journal:  J Surg Oncol       Date:  1979       Impact factor: 3.454

9.  Tumor self-seeding by circulating cancer cells.

Authors:  Mi-Young Kim; Thordur Oskarsson; Swarnali Acharyya; Don X Nguyen; Xiang H-F Zhang; Larry Norton; Joan Massagué
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

10.  A stochastic Markov chain model to describe lung cancer growth and metastasis.

Authors:  Paul K Newton; Jeremy Mason; Kelly Bethel; Lyudmila A Bazhenova; Jorge Nieva; Peter Kuhn
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

View more
  7 in total

1.  Estimating Tumor Growth Rates In Vivo.

Authors:  Anne Talkington; Rick Durrett
Journal:  Bull Math Biol       Date:  2015-10       Impact factor: 1.758

2.  Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.

Authors:  Aleksandra Markiewicz; Marzena Wełnicka-Jaśkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Hanna Majewska; Jolanta Szade; Anna J Żaczek
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

3.  Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.

Authors:  Eleonora Dondossola; Andrey S Dobroff; Serena Marchiò; Marina Cardó-Vila; Hitomi Hosoya; Steven K Libutti; Angelo Corti; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

4.  A conceptual review on systems biology in health and diseases: from biological networks to modern therapeutics.

Authors:  Pramod Rajaram Somvanshi; K V Venkatesh
Journal:  Syst Synth Biol       Date:  2013-09-18

5.  Modeling cancer-immune responses to therapy.

Authors:  L G dePillis; A Eladdadi; A E Radunskaya
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-04       Impact factor: 2.745

Review 6.  Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues.

Authors:  Munju Kim; Robert J Gillies; Katarzyna A Rejniak
Journal:  Front Oncol       Date:  2013-11-18       Impact factor: 6.244

7.  Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.

Authors:  Lin L Liu; Fei Li; William Pao; Franziska Michor
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.